Equities research analysts expect Amedisys Inc (NASDAQ:AMED) to report $385.92 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Amedisys’ earnings. The lowest sales estimate is $380.20 million and the highest is $390.87 million. Amedisys reported sales of $361.60 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.7%. The firm is expected to issue its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Amedisys will report full-year sales of $385.92 million for the current fiscal year, with estimates ranging from $1.51 billion to $1.54 billion. For the next fiscal year, analysts anticipate that the company will post sales of $1.61 billion per share, with estimates ranging from $1.60 billion to $1.63 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Amedisys.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. Amedisys’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 EPS.

Several analysts have recently issued reports on AMED shares. Benchmark Co. reiterated a “hold” rating and issued a $57.00 price objective (up from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Zacks Investment Research cut Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $57.00 price objective on shares of Amedisys in a research note on Friday, April 28th. Royal Bank Of Canada reiterated a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research note on Monday, June 5th. Finally, Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Wednesday, May 3rd. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $56.50.

In related news, insider Scott G. Ginn sold 23,828 shares of the firm’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $58.62, for a total value of $1,396,797.36. Following the completion of the sale, the insider now owns 13,018 shares in the company, valued at $763,115.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bruce D. Perkins acquired 500 shares of Amedisys stock in a transaction that occurred on Thursday, May 25th. The stock was purchased at an average price of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares of the company’s stock, valued at $795,727.39. The disclosure for this purchase can be found here. In the last three months, insiders have sold 56,828 shares of company stock worth $3,350,922. Corporate insiders own 2.80% of the company’s stock.

A number of large investors have recently made changes to their positions in AMED. Great West Life Assurance Co. Can increased its stake in shares of Amedisys by 2.8% in the second quarter. Great West Life Assurance Co. Can now owns 41,182 shares of the health services provider’s stock worth $2,585,000 after buying an additional 1,120 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of Amedisys by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 6,590 shares of the health services provider’s stock worth $414,000 after buying an additional 220 shares during the last quarter. Boston Advisors LLC increased its stake in shares of Amedisys by 36.3% in the second quarter. Boston Advisors LLC now owns 39,377 shares of the health services provider’s stock worth $2,473,000 after buying an additional 10,489 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Amedisys during the second quarter worth approximately $3,697,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Amedisys by 662.7% in the second quarter. Russell Investments Group Ltd. now owns 276,808 shares of the health services provider’s stock worth $17,387,000 after buying an additional 240,513 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/07/385-92-million-in-sales-expected-for-amedisys-inc-nasdaqamed-this-quarter-updated.html.

Shares of Amedisys (NASDAQ:AMED) traded down 3.76% during midday trading on Thursday, reaching $46.86. The company’s stock had a trading volume of 1,939,138 shares. Amedisys has a one year low of $34.58 and a one year high of $65.91. The stock’s 50-day moving average is $61.28 and its 200-day moving average is $54.05. The company has a market capitalization of $1.58 billion, a P/E ratio of 34.71 and a beta of 0.94.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.